Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors

Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy

(2020) Giovanni Taccetti et al.   Diagnostics

Cystic fibrosis newborn screening: the importance of bloodspot sample quality

(2020) Iolo Doull et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Galactose-1-phosphate uridyltransferase dried blood spot quality control materials for newborn screening tests

(2015) Barbara W. Adam et al.   CLINICAL BIOCHEMISTRY

Thirty-years of screening for cystic fibrosis in East Anglia

(2012) Jacqui Calvin et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: Challenges in newborn dried blood spot screening

(2012) Bradford L. Therrell et al.   MOLECULAR GENETICS AND METABOLISM

The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States

(2011) B.W. Adam et al.   CLINICAL BIOCHEMISTRY

Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening

(2011) Michael J. Rock et al.   PEDIATRIC PULMONOLOGY

Clarification of Laboratory and Clinical Variables That Influence Cystic Fibrosis Newborn Screening With Initial Analysis of Immunoreactive Trypsinogen

(2009) M. Kloosterboer et al.   PEDIATRICS

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

(2008) Philip M. Farrell et al.   JOURNAL OF PEDIATRICS